

Roger Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7791097/publications.pdf>

Version: 2024-02-01

46
papers

684
citations

623574

14
h-index

610775

24
g-index

46
all docs

46
docs citations

46
times ranked

1042
citing authors

#	ARTICLE	IF	CITATIONS
1	Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review. <i>European Urology</i> , 2018, 73, 738-748.	0.9	112
2	The use of PET/CT in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 4-21.	2.0	70
3	TGF- β -mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. <i>Immunity</i> , 2022, 55, 115-128.e9.	6.6	62
4	Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease. <i>European Urology</i> , 2019, 75, 8-10.	0.9	31
5	Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature. <i>European Urology Oncology</i> , 2021, 4, 893-903.	2.6	31
6	Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design. <i>Journal of Urology</i> , 2021, 205, 1612-1621.	0.2	31
7	Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin. <i>European Urology</i> , 2020, 78, 387-399.	0.9	28
8	Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer. <i>European Urology Oncology</i> , 2021, 4, 651-658.	2.6	25
9	Efficacy of Mycobacterium Phlei Cell Wall-Nucleic Acid Complex (MCNA) in BCG-Unresponsive Patients. <i>Bladder Cancer</i> , 2017, 3, 65-71.	0.2	24
10	Endoscopic Approaches to Upper Tract Urothelial Carcinoma. <i>Urologic Clinics of North America</i> , 2018, 45, 267-286.	0.8	23
11	Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy. <i>Communications Biology</i> , 2020, 3, 784.	2.0	21
12	Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer. <i>Nature Reviews Urology</i> , 2021, 18, 543-555.	1.9	20
13	Intraoperative Conversion From Partial to Radical Nephrectomy: Incidence, Predictive Factors, and Outcomes. <i>Urology</i> , 2018, 116, 114-119.	0.5	19
14	Role of Radical Cystectomy in Non-Organ Confined Bladder Cancer: A Systematic Review. <i>Bladder Cancer</i> , 2018, 4, 31-40.	0.2	15
15	Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 140-149.	2.0	15
16	The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin. <i>BJU International</i> , 2021, 128, 65-71.	1.3	13
17	Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 796.e1-796.e6.	0.8	13
18	Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious?. <i>European Urology</i> , 2018, 74, 405-408.	0.9	12

#	ARTICLE	IF	CITATIONS
19	Unraveling the Mechanism of the Antitumor Activity of Bacillus Calmette-Guérin. <i>European Urology</i> , 2021, 80, 1-3.	0.9	11
20	The role of metastatic burden in cytoreductive/consolidative radical cystectomy. <i>World Journal of Urology</i> , 2019, 37, 2691-2698.	1.2	10
21	The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-Guérin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data. <i>Journal of Urology</i> , 2020, 203, 283-291.	0.2	10
22	Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. <i>Journal of Urology</i> , 2021, 206, 548-557.	0.2	9
23	Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2019, 76, 4-6.	0.9	8
24	Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. <i>European Urology Oncology</i> , 2019, 2, 286-293.	2.6	8
25	Malignant solitary fibrous tumour of the prostate: four cases emphasising significant histological and immunophenotypical overlap with sarcomatoid carcinoma. <i>Pathology</i> , 2020, 52, 643-648.	0.3	8
26	Applying translabial ultrasound to detect synthetic slings-You can do it too! A comparison of urology trainees to an attending radiologist. <i>Neurourology and Urodynamics</i> , 2017, 36, 1763-1769.	0.8	6
27	Detection and Treatment of Primary Prostatic Melanoma. <i>Urology</i> , 2019, 123, 16-19.	0.5	6
28	Time interval from transurethral resection of bladder tumour to bacille Calmette-Guérin induction does not impact therapeutic response. <i>BJU International</i> , 2021, 128, 634-641.	1.3	5
29	New discoveries in the molecular landscape of bladder cancer. <i>F1000Research</i> , 2016, 5, 2875.	0.8	5
30	Current technique and results for extended pelvic lymph node dissection during robot-assisted radical prostatectomy. <i>Investigative and Clinical Urology</i> , 2016, 57, S155.	1.0	4
31	Secondary Tumors After Urinary Diversion. <i>Urologic Clinics of North America</i> , 2018, 45, 91-99.	0.8	4
32	Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 354.e19-354.e26.	0.8	4
33	Effects of thiazolidinedione in patients with active bladder cancer. <i>BJU International</i> , 2018, 121, 244-251.	1.3	3
34	Extended Pelvic Lymph Node Dissection in Bladder Cancer. <i>Journal of Endourology</i> , 2018, 32, S-49-S-54.	1.1	3
35	The Who, What, When, Where, and Why of Bacillus Calmette-Guérin-unresponsive Bladder Cancer. <i>European Urology</i> , 2021, 79, 437-439.	0.9	3
36	Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease. <i>Bladder Cancer</i> , 2017, 3, 147-148.	0.2	2

#	ARTICLE	IF	CITATIONS
37	Characterization of Glomus Tumors of the Kidney. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e253-e256.	0.9	2
38	Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer. <i>BJU International</i> , 2021, 128, 568-574.	1.3	2
39	Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer following Radiation Therapy: A Combined Analysis of Two Centers. <i>Journal of Urology</i> , 2021, 206, 646-654.	0.2	2
40	Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter. <i>Bladder Cancer</i> , 2022, 8, 113-117.	0.2	2
41	Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes. <i>European Urology Oncology</i> , 2021, , .	2.6	1
42	Oncologic Equipose Between Robotic and Open Radical Cystectomy. <i>Journal of Endourology</i> , 2021, 35, 1168-1176.	1.1	1
43	Reply to Yubo Yang, Xin Wei, and Ping Han's Letter to the Editor re: Roger Li, Philippe E. Spiess, Scott M. Gilbert, Andrea Necchi. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. <i>Eur Urol</i> 2019;76:4-6. <i>European Urology</i> , 2019, 76, e34.	0.9	0
44	Reply by Authors. <i>Journal of Urology</i> , 2021, 205, 1620-1621.	0.2	0
45	Re: Andrea Necchi, Laura Marandino, Daniele Raggi, et al. Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer? <i>Eur Urol</i> 2021;79:713-6. <i>European Urology</i> , 2021, 80, e99.	0.9	0
46	Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, , .	0.8	0